Frontiers in Pharmacology (Nov 2023)
Genome-wide CRISPR/Cas9 screening for drug resistance in tumors
- Zhongyan Zhang,
- Zhongyan Zhang,
- Hailiang Wang,
- Hailiang Wang,
- Hailiang Wang,
- Qian Yan,
- Qian Yan,
- Jinwei Cui,
- Jinwei Cui,
- Yubin Chen,
- Yubin Chen,
- Shiye Ruan,
- Shiye Ruan,
- Jiayu Yang,
- Jiayu Yang,
- Zelong Wu,
- Zelong Wu,
- Mingqian Han,
- Mingqian Han,
- Shanzhou Huang,
- Qi Zhou,
- Qi Zhou,
- Chuanzhao Zhang,
- Baohua Hou,
- Baohua Hou
Affiliations
- Zhongyan Zhang
- Department of General Surgery, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China
- Zhongyan Zhang
- The Second School of Clinical Medicine, Southern Medical University, Guangzhou, China
- Hailiang Wang
- Department of General Surgery, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China
- Hailiang Wang
- The Second School of Clinical Medicine, Southern Medical University, Guangzhou, China
- Hailiang Wang
- Department of Hepatobiliary Surgery, Weihai Central Hospital Affiliated to Qingdao University, Weihai, China
- Qian Yan
- Department of General Surgery, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China
- Qian Yan
- School of Medicine, South China University of Technology, Guangzhou, China
- Jinwei Cui
- Department of General Surgery, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China
- Jinwei Cui
- School of Medicine, South China University of Technology, Guangzhou, China
- Yubin Chen
- Department of General Surgery, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China
- Yubin Chen
- School of Medicine, South China University of Technology, Guangzhou, China
- Shiye Ruan
- Department of General Surgery, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China
- Shiye Ruan
- The Second School of Clinical Medicine, Southern Medical University, Guangzhou, China
- Jiayu Yang
- Department of General Surgery, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China
- Jiayu Yang
- The Second School of Clinical Medicine, Southern Medical University, Guangzhou, China
- Zelong Wu
- Department of General Surgery, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China
- Zelong Wu
- The Second School of Clinical Medicine, Southern Medical University, Guangzhou, China
- Mingqian Han
- Department of General Surgery, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China
- Mingqian Han
- The Second School of Clinical Medicine, Southern Medical University, Guangzhou, China
- Shanzhou Huang
- Department of General Surgery, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China
- Qi Zhou
- Department of Liver Surgery, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China
- Qi Zhou
- Department of General Surgery, Hui Ya Hospital of the First Affiliated Hospital, Sun Yat-Sen University, Huizhou, Guangdong, China
- Chuanzhao Zhang
- Department of General Surgery, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China
- Baohua Hou
- Department of General Surgery, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China
- Baohua Hou
- The Second School of Clinical Medicine, Southern Medical University, Guangzhou, China
- DOI
- https://doi.org/10.3389/fphar.2023.1284610
- Journal volume & issue
-
Vol. 14
Abstract
Genome-wide clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated nuclease 9 (Cas9) screening is a simple screening method for locating loci under specific conditions, and it has been utilized in tumor drug resistance research for finding potential drug resistance-associated genes. This screening strategy has significant implications for further treatment of malignancies with acquired drug resistance. In recent years, studies involving genome-wide CRISPR/Cas9 screening have gradually increased. Here we review the recent application of genome-wide CRISPR/Cas9 screening for drug resistance, involving mitogen-activated protein kinase (MAPK) pathway inhibitors, poly (ADP-ribose) polymerase inhibitors (PARPi), alkylating agents, mitotic inhibitors, antimetabolites, immune checkpoint inhibitors (ICIs), and cyclin-dependent kinase inhibitors (CDKI). We summarize drug resistance pathways such as the KEAP1/Nrf2 pathway MAPK pathway, and NF-κB pathway. Also, we analyze the limitations and conditions for the application of genome-wide CRISPR/Cas9 screening techniques.
Keywords
